Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
News
Nature Biotechnology 25, 1333–1334 (1 December 2007) | doi:10.1038/nbt1207-1333
Proposed changes to patent code loom over biotech industry
Abstract
In response to a suit filed by London-based GlaxoSmithKline (GSK), the US District Court for the Eastern District of Virginia issued an injunction on 31 October against proposed changes to the US patent code. The order came just one day before the changes were to take effect, leaving the fate of biotech's much-valued intellectual property (IP) in the court's hands.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
